Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,685 | 471 | 2,148 |
| Samples | 1,185 | 267 | 899 |
| Peptides | 1,044 | 206 | 851 |
Function
MAP1A · Microtubule associated protein 1A
This gene encodes a protein that belongs to the microtubule-associated protein family. The proteins of this family are thought to be involved in microtubule assembly, which is an essential step in neurogenesis. The product of this gene is a precursor polypeptide that presumably undergoes proteolytic processing to generate the final MAP1A heavy chain and LC2 light chain. Expression of this gene is almost exclusively in the brain. Studies of the rat microtubule-associated protein 1A gene suggested a role in early events of spinal cord development. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 995 amino-acid changes on canonical ENST00000300231 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MAP1A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MAP1A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 17/40 42% | 0/0 0% |
| Chordoma | 1/7 14% | 1/13 8% |
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Endometrial Carcinoma | 11/42 26% | 39/612 6% |
| Melanoma | 20/210 10% | 133/1899 7% |
| Acute Myeloid Leukemia | 6/90 7% | 0/0 0% |
| Cervical Carcinoma | 7/35 20% | 15/422 4% |
| Colorectal Carcinoma | 26/143 18% | 115/3239 4% |
| Other Solid Cancers | 5/94 5% | 58/1515 4% |
| Bladder Carcinoma | 6/58 10% | 32/956 3% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Hodgkins Lymphoma | 3/16 19% | 2/122 2% |
| Gastric Carcinoma | 6/74 8% | 61/1809 3% |
| Non-Small Cell Lung Carcinoma | 23/304 8% | 37/1390 3% |
| Burkitts Lymphoma | 7/32 22% | 1/196 1% |
| Other Sarcomas | 10/69 14% | 16/699 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 19/810 2% |
| Neuroendocrine Tumour | 13/154 8% | 6/577 1% |
| Head and Neck Carcinoma | 4/85 5% | 39/1574 2% |
| Germ Cell Tumour | 3/25 12% | 2/169 1% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Esophageal Squamous Cell Carcinoma | 8/51 16% | 57/2550 2% |
| Esophageal Carcinoma | 3/23 13% | 15/769 2% |
| Hepatocellular Carcinoma | 7/46 15% | 40/2210 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Ovarian Carcinoma | 7/109 6% | 14/998 1% |
| Breast Carcinoma | 14/144 10% | 49/3264 2% |
| Non-Cancerous | 4/104 4% | 13/830 2% |
Mutation Distribution
Where MAP1A is mutated · all tissues, split by cell line vs tissue
How many mutations in MAP1A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,685 mutations in MAP1A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|